

Sickle Cell Disease Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

<https://marketpublishers.com/r/SD627DFAEA2EN.html>

Date: November 2017

Pages: 201

Price: US\$ 4,400.00 (Single User License)

ID: SD627DFAEA2EN

Abstracts

Drastic reduction of total RBC count is called as anaemia. It is also defined as the inability of carrying the appropriate amounts of oxygen by blood. Sickle cell diseases are the type of blood disorders which are genetically inherited. Sickle-cell anaemia is the common type of SCD in which sickle-shaped cell is formed. Generally, sickle cell disease starts taking shape at the early age i.e., within a year after birth which leads to several health issues like attacks of pain which are also called as the sickle-cell crisis, limbs swelling, bacterial infections etc. Chronic pain can be developed along with the age. Sickle-cell diseases arise when an individual inherited by abnormal copies of Hg gene from each parent.

Sickle Cell Diseases Treatment Market is driven by the increasing prevalence of sickle cell anaemia in the developed, developing as well as underdeveloped economies. In addition to this unmet needs are highly available, a rise in product pipelines for the treatment of SCD is anticipated to pose great demand for the market. Sickle cell disease treatment market is propelled by rising support by the regulatory bodies and government in the form of investments, fast-track approvals for the discovery of newer treatments. Sickle cell anaemia treatment market is restrained by slow adoption of treatments due to the cost associated with it, the absence of a permanent cure for this disease and complications associated with treatment.

Sickle Cell Diseases Treatment Market is segmented on the basis of disease type, therapy, drug class, distribution channel, and geography.

On the basis of disease type, the global Sickle Cell Diseases Treatment Market treatment is segmented as:

Sickle beta thalassemia

Sickle haemoglobin C disease

Sickle cell anaemia

Others

On the basis of therapy, the global Sickle Cell Diseases Treatment Market is segmented as:

Bone Marrow Transplant

Blood Transfusion

Gene Therapy

On the basis of the drug class, the global Sickle Cell Diseases Treatment Market is segmented as:

Antibiotics

Analgesics

Antimetabolite (Hydroxyurea)

Others

On the basis of the distribution channel, the global Sickle Cell Diseases Treatment Market is segmented as:

Hospital Pharmacies

Retail Pharmacies

Others

Burgeoning prevalence of sickle cell disease has expected to drive the market. As per Centre for Disease Control and Prevention, in 2016, about 100,000 individuals in U.S. are affected by the sickle cell diseases. Black or the African Americans are commonly more susceptible to sickle cell diseases. One in thirteen babies who belongs to the black race are born with SCD's. Researchers have moved ahead to treat SCD by antibiotics to genome level. Researchers from the Stanford School of Medicine corrected the genes successfully which are carrying a gene for SCD and transplanted them with the healthy cells. With the help of Clustered Regularly Interspaced Short Palindromic Repeat technique (CRISPR), researchers have replaced the SCD cell genes with one which doesn't carry those genes. In 2016, Infosys has donated USD 1.11 million for the stem cell research to develop gene therapies for the disorders like haemophilia and sickle cell disease.

Based on the geographical regions, a global Sickle Cell Diseases Treatment Market is segmented into Latin America, Europe, North America, the Middle East and Africa, and Asia Pacific. North America is dominating the sickle cell anaemia treatment market due to the increase in activities in R&D, high accessibility of developed healthcare infrastructure and high reimbursement policies are attributing for the growth of the SCD treatment market in the region. Owing to the high prevalence rate of disease in Asia Pacific and African regions is favouring the growth of SCD treatment market. Asia-Pacific is one of the speedy growing markets due to the funding of the various industry players for stem cell research

Some of the sickle cell disease treatment providers are Biogen (U.S.), Gamida Cell (Israel), Genetix Pharmaceuticals Inc. (U.S.), Sangamo Biosciences (U.S.), Alnylam Pharmaceuticals, Inc. (U.S.), Acceleron Pharma (U.S.), Global Blood Therapeutics Inc. (U.S.), Emmaus Medical, Inc. (U.S.), Novartis AG (Switzerland) and Bristol-Myers Squibb Company (U.S.).

In July 2017, Emmaus Medical Inc. Endari (L-glutamine oral powder) received U.S. FDA approval to treat the patients with age of five years and older having sickle cell disease

In 2016 Novartis AG acquired Selexys Pharmaceuticals in order to expand product offerings related to blood disorders and diseases

REPORT OUTLINE:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET INTRODUCTION

2.1. Global Sickle Cell Disease Treatment Market– Taxonomy

2.2. Global Sickle Cell Disease Treatment Market–Definitions

2.2.1. Disease Type

2.2.2. Therapy

3. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Sickle Cell Disease Treatment Market Dynamics – Factors Impact Analysis

3.6. Global Sickle Cell Disease Treatment Market– Recent Market Introductions

4. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET FORECAST, BY DISEASES TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Sickle Beta Thalassemia

5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Sickle Haemoglobin C Disease

5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Sickle Cell Anaemia

- 5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.3.3. Market Opportunity Analysis

5.4. Others

- 5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.4.3. Market Opportunity Analysis

6. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET FORECAST, BY THERAPY, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Bone Marrow Transplant

- 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.1.3. Market Opportunity Analysis

6.2. Blood Transfusion

- 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.2.3. Market Opportunity Analysis

6.3. Gene Therapy

- 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.3.3. Market Opportunity Analysis

7. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET FORECAST, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Antibiotics

- 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.1.3. Market Opportunity Analysis

7.2. Analgesics

- 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.2.3. Market Opportunity Analysis

7.3. Antimetabolites

- 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.3.3. Market Opportunity Analysis

7.4. Others

- 7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.4.3. Market Opportunity Analysis

8. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Hospitals

- 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.1.3. Market Opportunity Analysis

8.2. Retail Pharmacies

- 8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.2.3. Market Opportunity Analysis

8.3. Others

- 8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.3.3. Market Opportunity Analysis

9. GLOBAL SICKLE CELL DISEASE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America

- 9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 9.1.3. Market Opportunity Analysis

9.2. Europe

- 9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 9.2.3. Market Opportunity Analysis

9.3. Asia-Pacific

- 9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 9.3.3. Market Opportunity Analysis

9.4. Latin America

- 9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.4.3. Market Opportunity Analysis

9.5. Middle East and Africa

9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

9.5.3. Market Opportunity Analysis

9.6. Global Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Region, 2017 – 2023

10. NORTH AMERICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Diseases Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.1.1. Sickle Beta Thalassemia

10.1.1.2. Sickle Haemoglobin C Disease

10.1.1.3. Sickle Cell Anaemia

10.1.1.4. Others

10.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Bone Marrow Transplant

10.1.2.2. Blood Transfusion

10.1.2.3. Gene Therapy

10.1.3. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Antibiotics

10.1.3.2. Analgesics

10.1.3.3. Antimetabolite (Hydroxyurea)

10.1.3.4. Others

10.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Hospitals

10.1.4.2. Diagnostic Centres

10.1.4.3. Blood Donation Centres

10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.1.5.1. U.S.

10.1.5.2. Canada

10.1.6. North America Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2017

– 2023

10.1.7. North America Sickle Cell Disease Treatment Market Dynamics – Trends

11. EUROPE SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Diseases Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.1.1. Sickle Beta Thalassemia

11.1.1.2. Sickle Haemoglobin C Disease

11.1.1.3. Sickle Cell Anaemia

11.1.1.4. Others

11.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Bone Marrow Transplant

11.1.2.2. Blood Transfusion

11.1.2.3. Gene Therapy

11.1.3. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Antibiotics

11.1.3.2. Analgesics

11.1.3.3. Antimetabolite (Hydroxyurea)

11.1.3.4. Others

11.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.4.1. Hospitals

11.1.4.2. Diagnostic Centres

11.1.4.3. Blood Donation Centres

11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.5.1. Germany

11.1.5.2. UK

11.1.5.3. France

11.1.5.4. Spain

11.1.5.5. Italy

11.1.5.6. Russia

11.1.5.7. Poland

11.1.5.8. Rest of Europe

11.1.6. Europe Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By

Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2017 – 2023

11.1.7. Europe Sickle Cell Disease Treatment Market Dynamics – Trends

12. ASIA-PACIFIC SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Diseases Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.1.1. Sickle Beta Thalassemia

12.1.1.2. Sickle Haemoglobin C Disease

12.1.1.3. Sickle Cell Anaemia

12.1.1.4. Others

12.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Bone Marrow Transplant

12.1.2.2. Blood Transfusion

12.1.2.3. Gene Therapy

12.1.3. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Antibiotics

12.1.3.2. Analgesics

12.1.3.3. Antimetabolite (Hydroxyurea)

12.1.3.4. Others

12.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Hospitals

12.1.4.2. Diagnostic Centres

12.1.4.3. Blood Donation Centres

12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

12.1.5.1. Japan

12.1.5.2. China

12.1.5.3. India

12.1.5.4. ASEAN

12.1.5.5. Australia & New Zealand

12.1.5.6. Rest of Asia-Pacific

12.1.6. Asia-Pacific Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2017 –

2023

12.1.7. Asia-Pacific Sickle Cell Disease Treatment Market Dynamics – Trends

13. LATIN AMERICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Diseases Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.1.1. Sickle Beta Thalassemia

13.1.1.2. Sickle Haemoglobin C Disease

13.1.1.3. Sickle Cell Anaemia

13.1.1.4. Others

13.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1. Bone Marrow Transplant

13.1.2.2. Blood Transfusion

13.1.2.3. Gene Therapy

13.1.3. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Antibiotics

13.1.3.2. Analgesics

13.1.3.3. Antimetabolite (Hydroxyurea)

13.1.3.4. Others

13.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.4.1. Hospitals

13.1.4.2. Diagnostic Centres

13.1.4.3. Blood Donation Centres

13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.5.1. Brazil

13.1.5.2. Mexico

13.1.5.3. Argentina

13.1.5.4. Venezuela

13.1.5.5. Rest of Latin America

13.1.6. Latin America Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2017 – 2023

13.1.7. Latin America Sickle Cell Disease Treatment Market Dynamics – Trends

14. MIDDLE EAST & AFRICA SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

14.1.1. Diseases Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.1.1. Sickle Beta Thalassemia

14.1.1.2. Sickle Haemoglobin C Disease

14.1.1.3. Sickle Cell Anaemia

14.1.1.4. Others

14.1.2. Therapy Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.2.1. Bone Marrow Transplant

14.1.2.2. Blood Transfusion

14.1.2.3. Gene Therapy

14.1.3. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.3.1. Antibiotics

14.1.3.2. Analgesics

14.1.3.3. Antimetabolite (Hydroxyurea)

14.1.3.4. Others

14.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.4.1. Hospitals

14.1.4.2. Diagnostic Centres

14.1.4.3. Blood Donation Centres

14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.5.1. Gulf Cooperation Council (GCC) Countries

14.1.5.2. Israel

14.1.5.3. South Africa

14.1.5.4. Rest of MEA

14.1.6. MEA Sickle Cell Disease Treatment Market- Opportunity Analysis Index - By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2017 – 2023

14.1.7. MEA Sickle Cell Disease Treatment Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players

15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

- 15.2.1. Biogen (U.S.)
- 15.2.2. Gamida Cell (Israel)
- 15.2.3. Genetix Pharmaceuticals Inc. (U.S.)
- 15.2.4. Sangamo Biosciences (U.S.)
- 15.2.5. Alnylam Pharmaceuticals, Inc. (U.S.)
- 15.2.6. Acceleron Pharma (U.S.)
- 15.2.7. Global Blood Therapeutics Inc. (U.S.)
- 15.2.8. Emmaus Medical, Inc. (U.S.)
- 15.2.9. Novartis AG (Switzerland)
- 15.2.10. Bristol-Myers Squibb Company (U.S.).

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Sickle Cell Disease Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/SD627DFAEA2EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SD627DFAEA2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

